Acadian Timber is a supplier of primary forest products in Eastern Canada and the Northeastern U.S. Co. owns and manages freehold timberlands in New Brunswick and Maine and provides management services relating to Crown licensed timberlands. Co. also owns and operates a forest nursery in Second Falls, New Brunswick. Co.'s products include softwood and hardwood sawlogs, pulpwood and biomass by-products.

Emergent BioSolutions is a life sciences company. The company is focused on preparedness and response products and solutions that address the following categories: Chemical, Biological, Radiological, Nuclear and Explosives; emerging infectious diseases; travel health; emerging health crises; acute/emergency care; and contract development and manufacturing. The company also has a development pipeline consisting of a mix of both pre-clinical and clinical-stage product candidates, including Trobigard? a combination drug-device auto injector product candidate. In addition, the company has a fully integrated molecule-to-market biologics CDMO business offerings (development services, drug substance and drug product).

Fastly is engaged in providing cloud computing services. The company provides developers with a programmable and reliable edge cloud platform that they adopt as their own. The company builts an edge cloud platform, designed from the ground up to be programmable and support agile software development. The company's platform consists of four primary components: a programmable edge, a software-defined modern network, safety in depth, and a philosophy of customer empowerment. The company's programmable edge provides developers with real-time visibility and control, where they can write and deploy code to push application logic to the edge. It supports application delivery processes.

FutureFuel, through its subsidiary, FutureFuel Chemical Company, manufactures various chemical products, bio-based products comprised of biofuels, and bio-based specialty chemical products. The company has two reporting segments: chemicals and biofuels. The company's chemicals segment manufactures chemical products that are sold to third party customers, and comprises two components: custom manufacturing (manufacturing chemicals for certain customers) and performance chemicals (multi-customer specialty chemicals). The company's biofuels segment primarily produces and sells biodiesel to its customers. In addition, the company sells petrodiesel in blends with its biodiesel and, from time to time, with no biodiesel added.

IGM Biosciences is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer.

Pennant Group is a holding company. Through its subsidiaries, the company is a provider healthcare services through 63 home health and hospice agencies and 52 senior living communities located throughout Arizona, California, Colorado, Idaho, Iowa, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming.

PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The company has the following products, Translarna? (ataluren) and Emflaza? (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. The company's gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC) deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.

SolarEdge Technologies designs, develops, and sells an intelligent inverter solution designed for power generation at the individual photovoltaic module level. The company's products consist mainly of power optimizers designed to maximize energy throughput from each and every module via constant tracking of Maximum Power Point individually per module; inverters, which invert direct current from the PV module to alternating current; a related cloud-based monitoring platform; and a storage solution that is used to increase energy independence and maximize self-consumption for homeowners by utilizing a battery that is sold separately by third party manufacturers, to store and supply power as needed.

Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. The company's main solar service offerings are provided through its lease and power purchase agreements, which it refers to as its Customer Agreements. While homeowners have the option to purchase a solar energy system outright from the company, a majority of its customers choose to buy solar as a service through its Customer Agreements. With its solar service offerings, the company installs solar energy systems on its customers' homes and provides them the solar power produced by those systems. In addition, the company monitors, maintains and insures the system during the term of the contract.

Take-Two Interactive Software is a developer, publisher and marketer of interactive entertainment for consumers. The company develops and publishes products principally through its two wholly-owned labels Rockstar Games and 2K, as well as its Private Division label and Social Point, a developer of mobile games. The company's products are designed for console gaming systems such as the Sony Computer Entertainment, Inc. PlayStation?4, Microsoft Corporation Xbox One?, and Xbox 360?, the Nintendo Switch, and personal computers, including smartphones and tablets. The company delivers its products through physical retail, digital download, online platforms and cloud streaming services.

Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies. The company develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-na?ve and TKI-pretreated patients. The company's main drug candidate is repotrectinib (TPX-0005). In addition to repotrectinib, the company's pipeline includes two clinical-stage multi-targeted kinase inhibitors, TPX-0022 (a MET/CSF1R/SRC inhibitor) and TPX-0046 (a RET/SRC inhibitor), and a preclinical ALK inhibitor, TPX-0131, which is entering IND-enabling studies. The company's fourth drug candidate, TPX-0131 is a preclinical ALK inhibitor.

Y-mAbs Therapeutics is a biopharmaceutical company focused on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. The company has a range of product pipeline, including two pivotal-stage product candidates: naxitamab and omburtamab, which target tumors that express GD2 and B7-H3, respectively. The company is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma (NB), and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, from NB.

Yandex is an internet and technology company that operates an internet search engine in Russia. Co. builds intelligent products and services powered by machine learning. Co.'s products and services are based on complex, unique technologies that are not easily replicated. Co. generates substantially all of its revenues from online advertising. Co. also generates revenues from its e-commerce offerings, classifieds and e-hailing service. Co.'s businesses are organized in the following operating segments: Search and Portal; E-commerce; Taxi; Classifieds and Experimental businesses.